Published in Curr Diab Rep on September 01, 2015
Microbiome, trimethylamine N-oxide, and cardiometabolic disease. Transl Res (2016) 0.80
Diet and Gut Microbial Function in Metabolic and Cardiovascular Disease Risk. Curr Diab Rep (2016) 0.78
Metaproteomics as a Complementary Approach to Gut Microbiota in Health and Disease. Front Chem (2017) 0.75
A plant-based diet for the prevention and treatment of type 2 diabetes. J Geriatr Cardiol (2017) 0.75
Visceral Congestion in Heart Failure: Right Ventricular Dysfunction, Splanchnic Hemodynamics, and the Intestinal Microenvironment. Curr Heart Fail Rep (2017) 0.75
A core gut microbiome in obese and lean twins. Nature (2008) 52.30
Diversity of the human intestinal microbial flora. Science (2005) 49.64
An obesity-associated gut microbiome with increased capacity for energy harvest. Nature (2006) 44.35
A human gut microbial gene catalogue established by metagenomic sequencing. Nature (2010) 43.63
The human microbiome project. Nature (2007) 28.53
The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A (2004) 26.56
TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest (2006) 17.49
Linking long-term dietary patterns with gut microbial enterotypes. Science (2011) 17.30
Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes (2007) 14.12
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature (2011) 13.53
Metabolite profiles and the risk of developing diabetes. Nat Med (2011) 12.22
A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature (2012) 11.68
Diet rapidly and reproducibly alters the human gut microbiome. Nature (2013) 11.04
Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A (2007) 9.71
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med (2013) 9.44
Diversity, stability and resilience of the human gut microbiota. Nature (2012) 9.09
The physiology of glucagon-like peptide 1. Physiol Rev (2007) 9.07
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med (2013) 8.21
Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev (2001) 7.19
Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature (2013) 6.07
Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology (2012) 6.04
Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A (2013) 5.88
The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem (2002) 5.53
Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J (2010) 5.43
Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A (2006) 5.19
Comparative analysis of pyrosequencing and a phylogenetic microarray for exploring microbial community structures in the human distal intestine. PLoS One (2009) 4.93
Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem (2003) 4.79
Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci U S A (2008) 4.45
Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes (2010) 3.39
An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut (2013) 3.07
Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes (2011) 3.06
Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr (2008) 2.77
Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol (2014) 2.48
Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes (2011) 2.46
The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun (2013) 2.31
γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell Metab (2014) 2.20
Phosphatidylcholine and choline homeostasis. J Lipid Res (2008) 2.17
L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clin Proc (2013) 2.10
Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur Heart J (2014) 2.08
The effect of meat protein and dietary fiber on colonic function and metabolism. II. Bacterial metabolites in feces and urine. Am J Clin Nutr (1979) 2.06
Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res (2014) 2.02
Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. Diabetologia (2011) 2.00
Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. Proc Natl Acad Sci U S A (2012) 1.99
Choline: an essential nutrient for public health. Nutr Rev (2009) 1.97
Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr (2009) 1.94
The microbiota of the gut in preschool children with normal and excessive body weight. Obesity (Silver Spring) (2012) 1.70
Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production. FASEB J (2000) 1.66
Review article: short chain fatty acids in health and disease. Aliment Pharmacol Ther (1998) 1.58
The contributory role of gut microbiota in cardiovascular disease. J Clin Invest (2014) 1.57
Transmission of atherosclerosis susceptibility with gut microbial transplantation. J Biol Chem (2014) 1.53
Human gut microbiota changes reveal the progression of glucose intolerance. PLoS One (2013) 1.51
Usual choline and betaine dietary intake and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. BMC Cardiovasc Disord (2007) 1.47
The clinical significance of betaine, an osmolyte with a key role in methyl group metabolism. Clin Biochem (2010) 1.43
Prior short-term consumption of resistant starch enhances postprandial insulin sensitivity in healthy subjects. Diabetologia (2003) 1.37
Divergent associations of plasma choline and betaine with components of metabolic syndrome in middle age and elderly men and women. J Nutr (2008) 1.37
Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis. Nat Commun (2015) 1.32
Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J Lipid Res (2014) 1.27
Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure. J Card Fail (2014) 1.24
Betaine and Trimethylamine-N-Oxide as Predictors of Cardiovascular Outcomes Show Different Patterns in Diabetes Mellitus: An Observational Study. PLoS One (2014) 1.23
Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. Int J Obes (Lond) (2011) 1.22
Whole blood choline and plasma choline in acute coronary syndromes: prognostic and pathophysiological implications. Clin Chim Acta (2007) 1.18
The interaction of short-chain fatty acids with adipose tissue: relevance for prevention of type 2 diabetes. Benef Microbes (2010) 1.18
Usefulness of elevations in serum choline and free F2)-isoprostane to predict 30-day cardiovascular outcomes in patients with acute coronary syndrome. Am J Cardiol (2009) 1.17
Repeatability and measurement error in the assessment of choline and betaine dietary intake: the Atherosclerosis Risk in Communities (ARIC) study. Nutr J (2009) 1.16
Acute effects of intravenous and rectal acetate on glucagon-like peptide-1, peptide YY, ghrelin, adiponectin and tumour necrosis factor-alpha. Br J Nutr (2009) 1.14
Carnitine metabolism to trimethylamine by an unusual Rieske-type oxygenase from human microbiota. Proc Natl Acad Sci U S A (2014) 1.13
Carnitine in type 2 diabetes. Ann N Y Acad Sci (2004) 1.10
Dietary trimethylamine N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet. J Biosci Bioeng (2014) 1.05
Butyrate and colorectal cancer: the role of butyrate transport. Curr Drug Metab (2013) 1.03
Homocysteine metabolism in diabetes. Biochem Soc Trans (2007) 1.02
Effects of short chain fatty acid producing bacteria on epigenetic regulation of FFAR3 in type 2 diabetes and obesity. Gene (2013) 0.97
Plasma lipids and betaine are related in an acute coronary syndrome cohort. PLoS One (2011) 0.97
Carnitine and type 2 diabetes. Diabetes Metab Res Rev (2009) 0.93
Long-term effects of dietary fiber on glucose tolerance and gastric emptying in noninsulin-dependent diabetic patients. Am J Clin Nutr (1983) 0.91
Dietary fiber and human health. N Engl J Med (1977) 0.90
Role of phosphatidylcholine during neuronal differentiation. IUBMB Life (2011) 0.90
Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. Am J Cardiol (2003) 0.90
Carnitine improves peripheral glucose disposal in non-insulin-dependent diabetic patients. Diabetes Res Clin Pract (1991) 0.90
Betaine and secondary events in an acute coronary syndrome cohort. PLoS One (2012) 0.90
Dietary choline and betaine intakes and risk of cardiovascular diseases: review of epidemiological evidence. ARYA Atheroscler (2011) 0.89
Choline and betaine food sources and intakes in Taiwanese. Asia Pac J Clin Nutr (2012) 0.86
Acetate, propionate and butyrate in plasma: determination of the concentration and isotopic enrichment by gas chromatography/mass spectrometry with positive chemical ionization. J Mass Spectrom (2001) 0.85
Variability of plasma and urine betaine in diabetes mellitus and its relationship to methionine load test responses: an observational study. Cardiovasc Diabetol (2012) 0.84
Assessment of urinary betaine as a marker of diabetes mellitus in cardiovascular patients. PLoS One (2013) 0.80
Interaction of carnitine with insulin-stimulated glucose metabolism in humans. Am J Physiol (1988) 0.79
Effective dosing of L-carnitine in the secondary prevention of cardiovascular disease: a systematic review and meta-analysis. BMC Cardiovasc Disord (2014) 0.79
Metabolic effects of L-carnitine on type 2 diabetes mellitus: systematic review and meta-analysis. Exp Clin Endocrinol Diabetes (2013) 0.77
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature (2011) 13.53
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 10.07
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med (2013) 9.44
HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail (2010) 6.37
Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol (2009) 5.76
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med (2015) 4.39
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 3.86
New gene functions in megakaryopoiesis and platelet formation. Nature (2011) 3.14
Genome-wide association study of coronary heart disease and its risk factors in 8,090 African Americans: the NHLBI CARe Project. PLoS Genet (2011) 3.07
Seventy-five genetic loci influencing the human red blood cell. Nature (2012) 2.77
Cardiorenal outcomes after slow continuous ultrafiltration therapy in refractory patients with advanced decompensated heart failure. J Am Coll Cardiol (2012) 2.75
Spironolactone in chronic heart failure:all's well that ends well. J Am Coll Cardiol (2003) 2.47
Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol (2008) 2.47
Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med (2008) 2.42
Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging (2009) 2.41
Response to cardiac resynchronization therapy in elderly patients (≥70 years) and octogenarians. Eur J Heart Fail (2012) 2.21
Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur Heart J (2014) 2.08
Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities. Blood (2011) 2.08
High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail (2010) 1.96
Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol (2008) 1.95
Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol (2008) 1.87
Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. J Am Coll Cardiol (2009) 1.86
Role of the CHADS2 score in the evaluation of thromboembolic risk in patients with atrial fibrillation undergoing transesophageal echocardiography before pulmonary vein isolation. J Am Coll Cardiol (2009) 1.78
Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail (2009) 1.75
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst (2010) 1.73
Pulmonary hypertension associated with advanced systolic heart failure: dysregulated arginine metabolism and importance of compensatory dimethylarginine dimethylaminohydrolase-1. J Am Coll Cardiol (2012) 1.69
Persistent hemodynamic benefits of cardiac resynchronization therapy with disease progression in advanced heart failure. J Am Coll Cardiol (2009) 1.64
Cardiac troponins in renal insufficiency: review and clinical implications. J Am Coll Cardiol (2002) 1.63
The contributory role of gut microbiota in cardiovascular disease. J Clin Invest (2014) 1.57
Early and late effects of cardiac resynchronization therapy on force-frequency relation and contractility regulating gene expression in heart failure patients. Heart Rhythm (2007) 1.57
Association of a genetic risk score with prevalent and incident myocardial infarction in subjects undergoing coronary angiography. Circ Cardiovasc Genet (2012) 1.54
Images in cardiovascular medicine. Tako-tsubo--like transient left ventricular dysfunction. Circulation (2003) 1.52
Time from emerging heart failure symptoms to cardiac resynchronisation therapy: impact on clinical response. Heart (2012) 1.45
The impact of left ventricular size on response to cardiac resynchronization therapy. Am Heart J (2011) 1.45
Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition. Arterioscler Thromb Vasc Biol (2009) 1.44
Immunoglobulins against tyrosine-nitrated epitopes in coronary artery disease. Circulation (2012) 1.42
QRS prolongation induced by cardiac resynchronization therapy correlates with deterioration in left ventricular function. Heart Rhythm (2012) 1.42
Potential effects of digoxin on long-term renal and clinical outcomes in chronic heart failure. J Card Fail (2013) 1.41
Pulmonary vascular response to exercise in symptomatic heart failure with reduced ejection fraction and pulmonary hypertension. Eur J Heart Fail (2014) 1.40
Dexamethasone, light anaesthesia, and tight glucose control (DeLiT) randomized controlled trial. Br J Anaesth (2013) 1.39
National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation (2007) 1.39
Incremental prognostic value of assessing left ventricular myocardial mechanics in patients with chronic systolic heart failure. J Am Coll Cardiol (2012) 1.37
A genome-wide association study for coronary artery disease identifies a novel susceptibility locus in the major histocompatibility complex. Circ Cardiovasc Genet (2012) 1.35
Ventricular geometry, strain, and rotational mechanics in pulmonary hypertension. Circulation (2010) 1.34
Improved prediction of cardiovascular disease based on a panel of single nucleotide polymorphisms identified through genome-wide association studies. Circ Cardiovasc Genet (2010) 1.23
Protein carbamylation predicts mortality in ESRD. J Am Soc Nephrol (2013) 1.22
Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest (2013) 1.21
Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail (2013) 1.19
Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. Circulation (2010) 1.18
Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. J Lipid Res (2010) 1.18
Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery. Circulation (2004) 1.17
Differential response to cardiac resynchronization therapy and clinical outcomes according to QRS morphology and QRS duration. J Am Coll Cardiol (2012) 1.15
Right atrial volume index in chronic systolic heart failure and prognosis. JACC Cardiovasc Imaging (2009) 1.12
Fasting 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography to detect metabolic changes in pulmonary arterial hypertension hearts over 1 year. Ann Am Thorac Soc (2013) 1.11
Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: importance of sustained decongestion. J Am Coll Cardiol (2013) 1.10
Lack of significant renal tubular injury despite acute kidney injury in acute decompensated heart failure. Eur J Heart Fail (2012) 1.10
Abdominal contributions to cardiorenal dysfunction in congestive heart failure. J Am Coll Cardiol (2013) 1.10
Comparative genome-wide association studies in mice and humans for trimethylamine N-oxide, a proatherogenic metabolite of choline and L-carnitine. Arterioscler Thromb Vasc Biol (2014) 1.08
Relation of systemic and urinary neutrophil gelatinase-associated lipocalin levels to different aspects of impaired renal function in patients with acute decompensated heart failure. Am J Cardiol (2012) 1.08
Cardiac troponins in renal insufficiency and other non-ischemic cardiac conditions. Prog Cardiovasc Dis (2005) 1.07
Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link. J Am Coll Cardiol (2004) 1.06
Prognostic role of pulmonary arterial capacitance in advanced heart failure. Circ Heart Fail (2012) 1.06
Right ventricular response to intensive medical therapy in advanced decompensated heart failure. Circ Heart Fail (2010) 1.06
Changes in intrathoracic impedance are associated with subsequent risk of hospitalizations for acute decompensated heart failure: clinical utility of implanted device monitoring without a patient alert. J Card Fail (2009) 1.05
Acute decompensated heart failure: update on new and emerging evidence and directions for future research. J Card Fail (2013) 1.04
Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail (2009) 1.04
Indications for cardiac resynchronization therapy: 2011 update from the Heart Failure Society of America Guideline Committee. J Card Fail (2012) 1.02
Association between the chromosome 9p21 locus and angiographic coronary artery disease burden: a collaborative meta-analysis. J Am Coll Cardiol (2013) 1.02
Long-term reverse remodeling with cardiac resynchronization therapy: results of extended echocardiographic follow-up. J Am Coll Cardiol (2010) 1.00
National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: Analytical issues for biomarkers of heart failure. Circulation (2007) 1.00
Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. J Card Fail (2012) 1.00
CD36 and Na/K-ATPase-α1 form a proinflammatory signaling loop in kidney. Hypertension (2012) 0.99
Choline Diet and Its Gut Microbe-Derived Metabolite, Trimethylamine N-Oxide, Exacerbate Pressure Overload-Induced Heart Failure. Circ Heart Fail (2015) 0.99
Usefulness of Isosorbide Dinitrate and Hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure. Am J Cardiol (2009) 0.99
Site-specific nitration of apolipoprotein A-I at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional. J Biol Chem (2014) 0.98
Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events. Circ Heart Fail (2012) 0.97
Renal dysfunction is a stronger determinant of systemic neutrophil gelatinase-associated lipocalin levels than myocardial dysfunction in systolic heart failure. J Card Fail (2011) 0.97
Genetic contribution of the leukotriene pathway to coronary artery disease. Hum Genet (2011) 0.96
Function and distribution of apolipoprotein A1 in the artery wall are markedly distinct from those in plasma. Circulation (2013) 0.96
Determinants of dynamic changes in serum creatinine in acute decompensated heart failure: the importance of blood pressure reduction during treatment. Eur J Heart Fail (2013) 0.95
Single exhaled breath metabolomic analysis identifies unique breathprint in patients with acute decompensated heart failure. J Am Coll Cardiol (2013) 0.94
Isolated left ventricular non-compaction controversies in diagnostic criteria, adverse outcomes and management. Heart (2012) 0.94
Cardiac resynchronization therapy in CKD: a systematic review. Clin J Am Soc Nephrol (2013) 0.93
Prognostic evaluation of ambulatory patients with advanced heart failure. Am J Cardiol (2008) 0.93
Diminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney disease. J Am Heart Assoc (2013) 0.93
The transcription factor GATA-2 does not associate with angiographic coronary artery disease in the Ottawa Heart Genomics and Cleveland Clinic GeneBank Studies. Hum Genet (2009) 0.92
Risk prediction with serial myeloperoxidase monitoring in patients with acute chest pain. Clin Chem (2011) 0.92
Prompt reduction in intra-abdominal pressure following large-volume mechanical fluid removal improves renal insufficiency in refractory decompensated heart failure. J Card Fail (2008) 0.92
Translating metabolomics to cardiovascular biomarkers. Prog Cardiovasc Dis (2012) 0.92
Increased exhaled nitric oxide levels after exercise in patients with chronic systolic heart failure with pulmonary venous hypertension. J Card Fail (2012) 0.92
Device monitoring strategies in acute heart failure syndromes. Heart Fail Rev (2011) 0.91
The chromosome 9p21.3 coronary heart disease risk allele is associated with altered gene expression in normal heart and vascular tissues. PLoS One (2012) 0.91
Patterns of beta-blocker utilization in patients with chronic heart failure: experience from a specialized outpatient heart failure clinic. Am Heart J (2004) 0.91
Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques. J Nucl Cardiol (2014) 0.90
Prognostic value of cardiac troponin in chronic stable heart failure: a systematic review. Heart (2012) 0.90
Pharmacologic strategies to target oxidative stress in heart failure. Curr Heart Fail Rep (2012) 0.90
Comprehensive peroxidase-based hematologic profiling for the prediction of 1-year myocardial infarction and death. Circulation (2010) 0.90